PMN ProMIS Neurosciences: Indikator likuiditas cepet

The confirmed price history on this chart demonstrates the performance of ProMIS Neurosciences (PMN), where the coefficient is 7.79. Company management effectively protects intellectual property and maintains transparency in its neurodegeneration research and development. The business relies on alliances with specialized institutes to create antibodies against pathogenic proteins. Anticipation of clinical trial results serves as a key driver, while the market value already prices in capital expenditures.

The specifics of ProMIS Neurosciences (PMN) digital antibody modeling minimize physical assets, making the net cash and receivables coverage ratio a key indicator of solvency. This metric excludes illiquid inventory by offsetting short-term liabilities only against available cash and accounts receivable, allowing for an objective assessment of the company's financial stability and the risk of liquidity gaps.